FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington,	D.C.	20549
-------------	------	-------

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

OMB APPROVAL									
OMB Number:	3235-0287								
Estimated average burden									
hours per response:	0.5								

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b)

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person* Chapman Marcus (Last) (First) (Middle) C/O SERES THERAPEUTICS, INC. 200 SIDNEY STREET					Issuer Name and Ticker or Trading Symbol Seres Therapeutics, Inc. [MCRB] 3. Date of Earliest Transaction (Month/Day/Year) 02/04/2021								S. Relationship of Reporting Person(s) to Issuer (Check all applicable) Director 10% Owner Officer (give title Other (specify below) See Remarks					
(Street) CAMBR (City)	IDGE M	ÍA	02139 (Zip)		4. If	4. If Amendment, Date of Original Filed (Month/Day/Year)							6. Lir	ndividual or Joint/Group Filing (Check Applicable a) X Form filed by One Reporting Person Form filed by More than One Reporting Person				
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned																		
1. Title of Security (Instr. 3) 2. Trans Date				2. Trans	action				3. 4. Securit Transaction Disposed Code (Instr. 5)		rities Acquired (A)		5. Amou Securition	mount of curities reficially ned Following		: Direct r Indirect str. 4)	7. Nature of Indirect Beneficial Ownership	
								Code	v	Amount	(A) or (D)	Price	Transac (Instr. 3	ion(s)			(Instr. 4)	
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)																		
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution D if any (Month/Day/	ate, T	I. Fransac Code (Ir B)	of		6. Date Exercisable an Expiration Date (Month/Day/Year)		9	7. Title and Amo of Securities Underlying Derivative Secu (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number derivative Securities Beneficially Owned Following Reported Transaction (Instr. 4)	illy	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	Beneficial Ownership (Instr. 4)	
				C	Code	v	(A)	(D)	Date Exercisab		Expiration Date	Title	Amount or Number of Shares					
Restricted Stock Units	(1)	02/04/2021			A		12,000		(2)		(2)	Common Stock	12,000	\$0.00	12,000)	D	
Stock Option (Right to Buy)	\$26.34	02/04/2021			A		24,000		(3)	(02/03/2031	Common Stock	24,000	\$0.00	24,000)	D	

Explanation of Responses:

- 1. Each restricted stock unit represents a contingent right to receive one share of Issuer common stock.
- 2. The restricted stock units will vest and settle as to 25% of the restricted stock units on March 15, 2022. The remainder of the restricted stock units will vest and settle in 12 equal quarterly installments
- 3. The option will vest as to 25% of the shares on February 4, 2022. The remainder of the shares will vest in 12 equal quarterly installments thereafter.

Remarks:

SVP, Principal Financial and Accounting Officer

/s/ Thomas J. DesRosier, Attorney-in-fact for Marcus

02/08/2021

Chapman

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.